JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

JP Morgan analyst Chris Schott has maintained an Overweight rating on Regeneron Pharmaceuticals (NASDAQ: REGN) and has increased the price target from $900 to $950.